TheraPsil’s Fight to Secure Therapeutic Psilocybin Access for All Canadians
CEO Spencer Hawkswell calls current exemptions for terminally ill under Section 56 of Canada’s Controlled Drugs and Substances Act a “half-assed solution,” and is lobbying for more.